ASRT Assertio Holdings Inc.

Assertio Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results After the Close of Markets on Monday, March 9, 2020

Assertio Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results After the Close of Markets on Monday, March 9, 2020

LAKE FOREST, Ill., March 02, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announced that it will release fourth quarter and full year 2019 financial results on Monday, March 9, 2020, after the close of markets. Following the announcement, the Company will host a conference call beginning at 3:30 p.m. central standard time to discuss its results.

Participants can access the live webcast from the Investor Relations section of Assertio's website at . Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software.

Audio Conference Call:

U.S. Dial-in Number: 1-877-550-3745

International Dial-in Number: 1-281-973-6277

Conference ID: 2099224

An archived webcast replay will be available on the Company's website accessed by visiting .

About Assertio Therapeutics, Inc.



Assertio Therapeutics is committed to providing responsible solutions to advance patient care in the Company’s core areas of neurology, orphan and specialty medicines. Assertio currently markets two FDA-approved products and continues to identify, license and develop new products that offer enhanced options for patients that may be underserved by existing therapies.

To learn more about Assertio, visit .

Investor and Media Contact:



Dan Peisert

Senior Vice President and Chief Financial Officer



Source: Assertio Therapeutics, Inc.

EN
02/03/2020

Underlying

ASRTAssertio Holdings Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Assertio Holdings Inc.

 PRESS RELEASE
Free
ASRT Assertio Holdin...

Assertio Announces Leadership Transition

Assertio Announces Leadership Transition Appoints Industry Veteran and Current Director Mark L. Reisenauer as CEO, Effective Immediately Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the Current Range at That Time LAKE FOREST, Ill., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced that its Board of Directors (the “Board”) has appointed director Mark L. Reisenauer as the Company’s Chief Executive Officer (“CEO”), effective immediately. As part of this transition,...

October 28, 2025 1 EN
 PRESS RELEASE
Free
ASRT Assertio Holdin...

Assertio Presents First-Ever Real-World Study Showing Patient Experien...

Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV New data show how Sympazan is being used in daily clinical practice to treat patients with Lennox-Gastaut Syndrome (LGS), a severe form of childhood-onset epilepsyStudy addresses lack of awareness and real-world data with oral film formulation of clobazamNew data presented during poster session at 150th Annual Meeting of the American Neurological AssociationSYMPAZAN is the only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with LG...

September 15, 2025 1 EN
 PRESS RELEASE
Free
ASRT Assertio Holdin...

Assertio to Present New Data from Real-World Evidence Study of SYMPAZA...

Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association Poster presentation will feature new data for SYMPAZAN, the only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age or olderAbstract is now available on ANA2025 website LAKE FOREST, Ill., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commerci...

September 10, 2025 1 EN
 PRESS RELEASE
Free
ASRT Assertio Holdin...

Assertio to Participate in the HC Wainwright and Lake Street Conferenc...

Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025 LAKE FOREST, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) announced that members of its management team will host investor meetings at two investor conferences in New York City during September 2025. Company management will host investor meetings at the HC Wainwright Conference on Wednesday, September 10, 2025, taking place at the Lotte New York Palace Hotel. Investors can register and request meetings via their HC Wainwright repr...

September 3, 2025 1 EN
 PRESS RELEASE
Free
ASRT Assertio Holdin...

Assertio Reports Second Quarter 2025 Financial Results

Assertio Reports Second Quarter 2025 Financial Results Second Quarter Total Net Product Sales of $28.8 Million, Cash and Investments Increase to $98.2 Million Narrows Guidance on Continued Progress Implementing Long-Term Business Strategy LAKE FOREST, Ill., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs, today reported financial results for the second quarter ended June 30, 2025. Said Brendan O...

August 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch